News Agency
The Times

Akeso's sBLA for Ivonescimab in 1L Treatment of PD-L1 Positive NSCLC Accepted by NMPA

  • Written by PR Newswire

HONG KONG, July 29, 2024 /PRNewswire/ -- Akeso (9926.HK) is delighted to announce that the supplemental biologics license application (sBLA) for its independently developed, world's first-in-class PD-1/VEGF bispecific antibody drug, 依达方® (generic name: ivonescimab Injection), as a monotherapy for first-line treatment of...

Read more: Akeso's sBLA for Ivonescimab in 1L Treatment of PD-L1 Positive NSCLC Accepted by NMPA

Google Ads Agency Sydney: How to Generate More Qualified Leads With Paid Search

When someone searches Google for a service they need immediately, appearing at the right moment can be extremely valuable. Unlike many traditional marketing channels, paid search can place a business in front of people who are already researching a product... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion